Viking’s Liver Fat Reduction Data Portend A New Competitor In NASH
In a Phase II study, Viking’s VK2809, with the same mechanism as Madrigal’s MGL-3196, shows significant liver fat reduction in NAFLD patients, along with reduction in LDL cholesterol.
You may also be interested in...
Currently running a Phase IIb NASH trial with VK2809, Viking reported at EASL that 16-week data in a Phase II study of NAFLD patients showed sustained liver fat reduction after treatment ended.
Non-alcoholic steatohepatitis (NASH) was a focal point of EASL’s conference. Madrigal becomes the fifth company into Phase III in NASH, but Viking’s competing THR agonist is progressing also.
Gilead took a risky approach with selonsertib in NASH, pursuing a tough liver fibrosis benefit and failing, continuing a trend of disappointments outside of its antiviral franchises. Analysts don’t expect the second Phase III study in less-sick patients to succeed either.